

# Wnt signalling in colon cancer

<b>Submission date</b> 08/10/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 24/02/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 18/12/2017	<b>Condition category</b> Cancer	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Matthew Brookes

**Contact details**  
Royal Wolverhampton NHS Trust, New Cross Hospital  
Wolverhampton  
United Kingdom  
WV10 0QP  
-  
m.j.brookes@bham.ac.uk

## Additional identifiers

**Protocol serial number**  
9016

## Study information

**Scientific Title**  
Is the tumour suppressor adenomatous polyposis coli (APC) crucial to iron mediated colorectal carcinogenesis? A single centre observational clinical laboratory study

**Study objectives**  
Hypothesis and proof of concept:  
Our hypothesis is that increase in cellular iron import proteins (TfR1, DMT1) occur early in the

adenoma-carcinoma sequence through mutations in APC and lead to cellular iron loading. As demonstrated in our previous work the effects of this iron loading is to mediate increased Wnt signalling resulting in c-myc induction. This in turn serves to increase the expression of iron import proteins (TfR1, DMT1) and decrease the expression of iron export (ferroportin [FPN]) and storage (ferritin) proteins. Such a hypothesis explains how Wnt signalling controls iron metabolism and ensures that there is adequate cellular iron for ATP generation and cellular proliferation.

#### Experimental design:

To test such a hypothesis we aim to prospectively collect the following colorectal tissue from patients attending for colonoscopy:

1. Normal colonic mucosa in patients with no colorectal pathology (n = 30)
2. Polyps and matched normal colon (n = 30)
3. Colorectal cancers and matched normal colon (n = 30)

We also intend to collect serum and urine from the following patient groups:

4. Normal colonoscopy (n = 30)
5. Colorectal adenomas (n = 30)
6. Colorectal cancers (n = 30)

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Black Country Research Ethics Committee, 03/08/2010, ref: 10/H1202/40

#### Study design

Single-centre non-randomised observational clinical laboratory study

#### Primary study design

Observational

#### Study type(s)

Screening

#### Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Colorectal Cancer; Disease: Colon

#### Interventions

This will include the collection of tissue from normal colonic tissue, adenomatous polyps and colorectal cancers. Alongside this we will collect serum and urine to measure systemic iron transport proteins. Following collection of tissue we will determine the expression of APC and the cellular iron transport proteins utilising techniques including, mass spectrometry, western blotting, Real-Time PCR and immunohistochemistry. In each group of patients (normal, polyps or colorectal cancer) we will determine the expression of the iron transport proteins and determine if there are significant changes demonstrable.

Follow Up Length: 12 month(s); Study Entry : Registration only

#### Intervention Type

Other

**Phase**

Not Applicable

**Primary outcome(s)**

Measured at baseline, using the expression of proteins in the tissue and serum to detect the cellular and systemic iron transport proteins. The techniques used will include mass spectrometry, western blotting, real time PCR and immunohistochemistry.

**Key secondary outcome(s)**

No secondary outcome measures

**Completion date**

01/12/2011

## Eligibility

**Key inclusion criteria**

1. Aged between 60 - 75 years, either sex
2. Bowel cancer screening patients attending for colonoscopy

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

All

**Key exclusion criteria**

1. Unfit for colonoscopy
2. Previous colorectal cancer
3. Ongoing or previous cancer treatment (chemo-radiotherapy)

**Date of first enrolment**

01/11/2010

**Date of final enrolment**

01/12/2011

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**  
Royal Wolverhampton NHS Trust, New Cross Hospital  
Wolverhampton  
United Kingdom  
WV10 0QP

## Sponsor information

**Organisation**  
New Cross Hospital (UK)

**ROR**  
<https://ror.org/05w3e4z48>

## Funder(s)

**Funder type**  
Charity

**Funder Name**  
Digestive Disorders Foundation (CORE) (UK)

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	30/08/2012		Yes	No